Abstracts tagged "interleukins (IL)"

Abstract Number: 2168 • 2014 ACR/ARHP Annual Meeting
Extramedullary Myelopoiesis Drives Persistent Toll-like Receptor-Mediated Inflammation
Lehn K. Weaver¹ and Edward M. Behrens², ¹Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Pediatric Rheumatology, Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Many rheumatic diseases are driven by chronic, repeated activation of Toll-like receptors (TLR) causing the initiation and perpetuation of disease. However, TLR-activated innate immune…
Abstract Number: 311 • 2014 ACR/ARHP Annual Meeting
Inhibition of Natural Killer (NK) Cell Cytotoxicity By Interleukin-6 (IL-6): Implications for the Pathogenesis of Macrophage Activation Syndrome
Loredana Cifaldi¹, Giusi Prencipe², Ivan Caiello², Claudia Bracaglia², Raffaele Strippoli³ and Fabrizio De Benedetti Sr.², ¹Paediatric Haematology/Oncology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, ²Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, ³Cellular Biotechnologies and Haematology, Sapienza Rome University, Rome, Italy
Background/Purpose: MAS occurs frequently in patients with active systemic juvenile idiopathic arthritis(s-JIA) and because of the similarities with Haemophagocytic Lymphohistiocytosis (HLH) is classified among secondary…
Abstract Number: 2039 • 2014 ACR/ARHP Annual Meeting
Among Persons Assayed with Lower Serum Interleukin-1 Beta (IL-1β) Levels, Serum Androstenedione (Δ4A) and Testosterone (T) Were Significantly Lower in a Community-Based Cohort of Rheumatoid Arthritis Multi-Years before Clinical Onset (Pre-RA) Than in Non-RA Matched Control (CN) Subjects
Alfonse T. Masi, Azeem A. Rehman and Jean C. Aldag, Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Dysregulations in androgenic-anabolic (A-A) steroids and cytokines are recognized in RA and pre-RA subjects (Rheum Dis Clin N Am 2005; 31: 131-60). However, deviations…
Abstract Number: 81 • 2014 ACR/ARHP Annual Meeting
Elevated Peripheral Blood Leukocyte Inflammatory Gene Expression in Radiographic Progressors with Symptomatic Knee Osteoarthritis: NYU and OAI Cohorts
Mukundan Attur¹, Alexander Statnikov², Svetlana Krasnokutsky Samuels¹, Virginia B. Kraus³, Joanne Jordan⁴, Braxton D. Mitchell⁵, Michelle Yau⁶, Jyoti Patel¹, Constantin F. Aliferis², Marc C. Hochberg⁷, Jonathan Samuels¹ and Steven B. Abramson⁸, ¹Rheumatology, NYU Langone Medical Center, New York, NY, ²Center for Health Informatics and Bioinformatics, NYU Langone Medical Center, New York, NY, ³Medicine/Rheumatology, Duke University Medical Center, Durham, NC, ⁴Thurston Arthritis Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Departments of Medicine and Epidemiology & Public Health, University of Maryland School of Medicine, Baltimore, MD, ⁶Epidemiology and Public Health, University of Maryland, Baltimore,, MD, ⁷Medicine, University of Maryland School of Medicine, Baltimore, MD, ⁸Dept of Rheumatology/Medicine, NYU Langone Medical Center, New York, NY
Background/Purpose: We and others have demonstrated low grade inflammation exists in OA joint tissues, where it may contribute to disease pathogenesis. In the current studies…
Abstract Number: 1816 • 2014 ACR/ARHP Annual Meeting
Toll-like Receptor 4-Induced Interleukin-1 Defines the Intestinal Microbiome and Mucosal Immune Response in Arthritis-Prone IL-1 Receptor Antagonist Deficient Mice
Tom Ederveen¹, Rebecca Rogier², Jos Boekhorst¹, Harm Wopereis³, Johan Garssen³, Sacha van Hijum¹, Fons A.J. van de Loo², Marije I. Koenders², Wim B. van den Berg² and Shahla Abdollahi-Roodsaz⁴, ¹Centre for Molecular Bioinformatics Nijmegen (CMBI), Radboud university medical center, Nijmegen, Netherlands, ²Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ³Danone Research, Wageningen, Netherlands, ⁴Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose Interleukin-1 (IL-1) plays a pivotal role in inflammation and autoimmunity. Mice deficient in the IL-1 receptor antagonist (IL-1Ra-/-) spontaneously develop a T cell-driven autoimmune…
Abstract Number: 1746 • 2014 ACR/ARHP Annual Meeting
Involvement of IL-17-Producing MAIT Cells in the Pathogenesis of Rheumatoid Arthritis
Eri Hayashi¹, Asako Chiba², Mie Kitagaichi³, Kurisu Tada³, Ken Yamaji⁴, Naoto Tamura¹, Yoshinari Takasaki³ and Sachiko Miyake², ¹Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Immunology, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁴Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are a subset of innate-like lymphocytes which are restricted by the MHC-related molecule-1 (MR1) and express a semi-invariant TCRα…
Abstract Number: 1732 • 2014 ACR/ARHP Annual Meeting
Attenuation of Sclerodermatous Graft Versus Host Disease (sclGVHD) in IL4RA Receptor-Deficient Mice
Katia Urso¹, Kelly Tsang², Robert Lafyatis³ and Antonios O. Aliprantis², ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose Scleroderma is a rare autoimmune disease characterized by the accumulation of fibrotic tissue in multiple organs including the skin, gut and lungs. To date,…
Abstract Number: 1511 • 2014 ACR/ARHP Annual Meeting
COVA322: A Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases
Wibke Lembke, Bernd Schlereth, Julian Bertschinger, Dragan Grabulovski and Mathias Locher, Covagen AG, Schlieren, Switzerland
Background/Purpose: Biologic therapeutics such as TNF inhibitors have revolutionized the treatment of inflammatory diseases, including rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, there is still…
Abstract Number: 1491 • 2014 ACR/ARHP Annual Meeting
Discovery and Characterization of COVA322, a Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases
Dragan Grabulovski, Michela Silacci, Wibke Lembke, Wenjuan Zha, Richard Woods, Roger Santimaria, Julian Bertschinger and Mathias Locher, Covagen AG, Schlieren, Switzerland
Background/Purpose: Biologics such as TNF inhibitors have revolutionized the treatment of inflammatory diseases including rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, recent data suggest that…
Abstract Number: 1492 • 2014 ACR/ARHP Annual Meeting
Safety and Tolerability of NNC01140006, an Anti-IL-21 Monoclonal Antibody, at Multiple s.c. Dose Levels in Patients with Rheumatoid Arthritis
Frank Wagner¹, Birte Skrumsager² and Sergey Fitilev³, ¹Charité Research Org GmbH, Berlin, Germany, ²Novo Nordisk A/S, Søborg, Denmark, ³Department of Clinical Pharmacology, Municipal Clinic #2, Moscow, Russia
Background/Purpose A phase 1, randomised, double-blind, placebo-controlled, dose-escalation trial was conducted to assess the safety and tolerability of the anti-IL-21-antibody NNC0114-0006, in patients with active…
Abstract Number: 1459 • 2014 ACR/ARHP Annual Meeting
IL-22 Secreted By NKp44+NK Cells Promote the Proliferation of Synovium in Patients with Rheumatoid Arthritis By Activation of STAT3
Junqing Zhu¹, Juan Li¹ and Xiaoguang Chen², ¹Nanfang Hospital, College of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China, ²School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, China
Background/Purpose: Although CD3-CD56+NKp44+ natural Killer cells (NKp44+NK cells) have been linked to autoimmune diseases including inflammatory bowel disease, ankylosing spondylitis, and primary Sjogren's syndrome, the…
Abstract Number: 2695 • 2013 ACR/ARHP Annual Meeting
Host Genetic Background Disrupts The Relationship Between Microbiota and Gut Mucosal Tolerance Leading To Spondyloarthritis and Ileitis After a Dectin-1 Trigger
Linda Rehaume¹, Stanislas Mondot², Daniel Aguirre de Cárcer², Jared Velasco¹, Helen Benham¹, Sumaira Hasnain³, Jaclyn Bowman¹, Merja Ruutu¹, Philip Hansbro⁴, Michael McGuckin³, Mark Morrison² and Ranjeny Thomas¹, ¹University of Queensland Diamantina Institute, Brisbane, Australia, ²CSIRO Livestock Industries, Brisbane, Australia, ³Mater Medical Research Institute, Brisbane, Australia, ⁴Center for Asthma and Respiratory Disease and Hunter Medical Research Institute, Newcastle, Australia
Background/Purpose: Chronic inflammatory diseases known as spondyloarthropathies (SpA) including ankylosing spondylitis, psoriatic arthritis, reactive arthritis, and arthritis associated with inflammatory bowel disease, collectively affect 3%…
Abstract Number: 918 • 2013 ACR/ARHP Annual Meeting
Regulatory B Cells Suppress Skin Inflammation in a Murine Model of Psoriasis
Koichi Yanaba¹ and Shinichi Sato², ¹Dermatology, The University of Tokyo, Tokyo, Japan, ²Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Psoriasis is a cutaneous disorder characterized by widespread erythematous plaques with adherent scales. Recent studies have revealed that both T helper (Th) 17 and…
Abstract Number: 2500 • 2013 ACR/ARHP Annual Meeting
Mast Cells Are a Major Source Of IL-17 In Synovium and Extra-Articular Tissues In Spondyloarthritis Related Diseases
T. Noordenbos¹, I. Gofita¹, M. Alsina², E.W.M. Vogels³, A. A. te Velde³, J. D. Cañete⁴, Dominique L. Baeten⁵ and N. Yeremenko¹, ¹Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ²Department of Dermatology, Hospital Clinic de Barcelona, Barcelona, Spain, ³Tytgat Institute for Liver and Intestinal Research, Academic Medical Centre/University of Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁴Rheumatology, Hospital Clinic, Barcelona, Spain, ⁵Department of Clinical Immunology and Rheumatology Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: IL-17 plays a key role in the pathogenesis of spondyloarthritis (SpA) as demonstrated by a recent proof-of-concept trial with the anti-IL17A mAb secukinumab. The…
Abstract Number: 823 • 2013 ACR/ARHP Annual Meeting
Activation Of Liver X Receptors Inhibits Experimental Fibrosis By Interfering With Interleukin-6 Release From Macrophages
Christian Beyer¹, Jürgen Beer¹, Katrin Palumbo-Zerr¹, Pawel Zerr¹, Alfiya Distler¹, Clara Dees¹, Louis E. Munoz¹, Gerhard Krönke¹, Oliver Distler², Steve Anderson³, Georg A. Schett⁴ and Joerg H. W. Distler¹, ¹Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Lexicon Pharmaceuticals Inc., The Woodlands, TX, ⁴Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Liver X receptors (LXRs) are orphan nuclear receptors with emerging roles in metabolic and autoimmune diseases. Here, we investigated the role of LXRs in…

« Previous Page
1
…
6
7
8
9
10
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].